Pharma Stocks Under Pressure: Shares Drop Nearly 4 per cent Despite Diabetes and Obesity Drug Launch in UK Pharma Stocks Under Pressure: Shares Drop Nearly 4 per cent Despite Diabetes and Obesity Drug Launch in UK With GLP-1 therapies expected to be a significant revenue driver in the future, Biocon aims to strengthen its footprint in this segment. Abhishek Wani / Friday, February 28, 2025 0 74 Article rating: 4.3 With GLP-1 therapies expected to be a significant revenue driver in the future, Biocon aims to strengthen its footprint in this segment. Read more